NYSE:NVRO

Nevro - NVRO Stock Forecast, Price & News

$48.85

-1.93 (-3.80%)

(As of 08/19/2022 12:57 PM ET)

Add

Compare

Today's Range: $48.00
▼
$49.96
50-Day Range: $40.66
▼
$53.03
52-Week Range: $39.41
▼
$127.97

Volume: 6,139 shs
Average Volume: 501,987 shs
Market Capitalization: $1.73 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $71.10

Nevro MarketRank™ Forecast

Analyst Rating: Hold
2.18 Rating Score
Upside/Downside: 46.5% Upside
$71.10 Price Target
Short Interest: Bearish
5.86% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.90) to ($1.97) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

1040th out of 1,119 stocks

Surgical & Medical Instruments Industry

102nd out of 111 stocks

3.1

Analyst's Opinion

Consensus Rating
Nevro has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 4 buy ratings, 5 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $71.10, Nevro has a forecasted upside of 46.5% from its current price of $48.53.
Amount of Analyst Coverage
Nevro has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.86% of the float of Nevro has been sold short.
Short Interest Ratio / Days to Cover
Nevro has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Nevro does not currently pay a dividend.
Dividend Growth
Nevro does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NVRO.

1.8

News and Social Media Coverage

News Sentiment
Nevro has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.
MarketBeat Follows
3 people have added Nevro to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nevro insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.80% of the stock of Nevro is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Nevro are expected to grow in the coming year, from ($2.90) to ($1.97) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nevro is -12.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nevro is -12.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nevro has a P/B Ratio of 7.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Nevro (NYSE:NVRO) Stock

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on NVRO shares. Wells Fargo & Company decreased their target price on Nevro from $90.00 to $86.00 and set an "overweight" rating for the company in a research report on Thursday, August 4th. Citigroup decreased their price objective on Nevro from $78.00 to $68.00 in a report on Tuesday, May 17th. Morgan Stanley reduced their price target on shares of Nevro from $55.00 to $54.00 and set an "equal weight" rating for the company in a research report on Thursday, August 4th. StockNews.com upgraded shares of Nevro from a "sell" rating to a "hold" rating in a report on Thursday, July 21st. Finally, Truist Financial cut their price target on shares of Nevro to $45.00 in a research note on Friday, July 22nd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Nevro has an average rating of "Hold" and an average price target of $71.10.

Nevro Stock Performance

Nevro stock traded up $0.13 during mid-day trading on Thursday, reaching $50.78. 296,981 shares of the company's stock were exchanged, compared to its average volume of 567,975. Nevro has a one year low of $39.41 and a one year high of $127.97. The company has a quick ratio of 5.36, a current ratio of 6.65 and a debt-to-equity ratio of 0.81. The business's fifty day simple moving average is $45.72 and its 200 day simple moving average is $56.91. The firm has a market capitalization of $1.80 billion, a PE ratio of -12.73 and a beta of 0.96.

Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

NVRO Stock News Headlines

August 11, 2022 | benzinga.com

Nevro's Return On Capital Employed Overview - Benzinga

August 10, 2022 | businesswire.com

Global Pain Management Devices Market to 2031 - Featuring Abbott Laboratories, Baxter International and Medtronic Among Others - ResearchAndMarkets.com - Business Wire

August 10, 2022 | americanbankingnews.com

Oppenheimer Analysts Raise Earnings Estimates for Nevro Corp. (NYSE:NVRO)

August 9, 2022 | finance.yahoo.com

Nevro Announces Participation In Upcoming Investor Conferences

August 8, 2022 | americanbankingnews.com

Piper Sandler Trims Nevro (NYSE:NVRO) Target Price to $45.00

August 6, 2022 | americanbankingnews.com

Morgan Stanley Lowers Nevro (NYSE:NVRO) Price Target to $54.00

August 6, 2022 | americanbankingnews.com

Nevro (NYSE:NVRO) Shares Gap Down After Analyst Downgrade

August 5, 2022 | nasdaq.com

Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised - Nasdaq

August 4, 2022 | finance.yahoo.com

Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance - Yahoo Finance

August 4, 2022 | seekingalpha.com

Nevro Q2 results mixed, co cuts FY 2022 revenue guidance, sees wider FY adj. EBITDA loss - Seeking Alpha

August 3, 2022 | finance.yahoo.com

Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance

August 2, 2022 | seekingalpha.com

Boston Scientific to pay $85M to Nevro as part of settlement to resolve patent litigation - Seeking Alpha

August 2, 2022 | americanbankingnews.com

Nevro (NVRO) Set to Announce Quarterly Earnings on Wednesday

August 1, 2022 | nasdaq.com

Nevro And Boston Scientific Reach $85 Mln Settlement Of Ongoing Intellectual Property Litigations - Nasdaq

August 1, 2022 | finance.yahoo.com

Nevro and Boston Scientific Announce the Settlement of Their Ongoing Intellectual Property Litigations

July 30, 2022 | americanbankingnews.com

Analysts Set Nevro Corp. (NYSE:NVRO) PT at $77.00

July 21, 2022 | benzinga.com

Nevro to Present at the Canaccord Genuity 42nd Annual Growth Conference - Benzinga - Benzinga

July 21, 2022 | finance.yahoo.com

Nevro to Present at the Canaccord Genuity 42nd Annual Growth Conference

July 20, 2022 | finance.yahoo.com

Global Brain Implants Market, By Product Type, By Application, By End User, By Region, Competition Forecast & Opportunities, 2027 - Yahoo Finance

July 11, 2022 | finance.yahoo.com

Neurostimulation Devices Market Size is projected to reach USD 14 billion by 2030, growing at a CAGR of 13%: Straits Research - Yahoo Finance

July 11, 2022 | streetinsider.com

Form SC 13G/A NEVRO CORP Filed by: VANGUARD GROUP INC - StreetInsider.com

July 5, 2022 | finance.yahoo.com

Newly Released Clinical Data Demonstrates Substantial Improvement in Overall Health-Related Quality of Life in Patients with Painful Diabetic Neuropathy Treated with Nevro HFX Spinal Cord Stimulation Therapy

June 23, 2022 | finance.yahoo.com

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

June 10, 2022 | seekingalpha.com

Nevro (NVRO): FDA Approved Lower Back Pain Relief Without Opiates Or Surgery, A Hold - Seeking Alpha

June 7, 2022 | benzinga.com

Expert Ratings for Nevro - Benzinga - Benzinga

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

NVRO Company Calendar

Last Earnings: 11/07/2021
Today: 8/19/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:NVRO
CUSIP: N/A
CIK: 1444380
Web: www.nevro.com
Phone: (650) 251-0005
Fax: N/A
Employees: 945
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $71.10
High Stock Price Forecast: $97.00
Low Stock Price Forecast: $45.00
Forecasted Upside/Downside: +45.5%
Consensus Rating: Hold
Rating Score (0-4): 2.18
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.99)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-131,360,000.00
Net Margins: -35.96%
Pretax Margin: -35.85%
Return on Equity: -43.73%
Return on Assets: -21.60%

Debt

Debt-to-Equity Ratio: 0.81
Current Ratio: 6.65
Quick Ratio: 5.36

Sales & Book Value

Annual Sales: $386.90 million
Price / Sales: 4.47
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.50 per share
Price / Book: 7.52

Miscellaneous

Outstanding Shares: 35,390,000
Free Float: 34,397,000
Market Cap: $1.73 billion
Optionable: Optionable
Beta: 0.96

Key Executives

Mr. D. Keith Grossman (Age 62)
Chairman, CEO & Pres
Comp: $857.84k

Mr. Roderick H. MacLeod (Age 55)
Chief Financial Officer
Comp: $458.2k

Mr. Kashif Rashid (Age 48)
Gen. Counsel, Corp. Sec. & Chief Compliance Officer
Comp: $437.6k

Ms. Niamh Louise Pellegrini (Age 55)
Chief Commercial Officer
Comp: $482.4k

Mr. Patrick Schmitz (Age 62)
VP of Operations

Mr. Richard B. Carter (Age 51)
Chief Accounting Officer

Ms. Julie D. Dewey (Age 61)
Chief Corp. Communications & Investor Relations Officer

Mr. Michael Collier Carter (Age 50)
VP of Global Sales

Mr. Jon R. Shear
VP of Corp. Devel.

Ms. Lori M. Ciano (Age 59)
Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NVRO Stock - Frequently Asked Questions

Should I buy or sell Nevro stock right now?: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View NVRO analyst ratings or view top-rated stocks.
What is Nevro's stock price forecast for 2022?: 11 brokerages have issued 12 month price objectives for Nevro's stock. Their NVRO share price forecasts range from $45.00 to $97.00. On average, they predict the company's stock price to reach $71.10 in the next twelve months. This suggests a possible upside of 40.0% from the stock's current price.
View analysts price targets for NVRO or view top-rated stocks among Wall Street analysts.
How have NVRO shares performed in 2022?: Nevro's stock was trading at $81.07 on January 1st, 2022. Since then, NVRO shares have decreased by 37.4% and is now trading at $50.78.
View the best growth stocks for 2022 here.
When is Nevro's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our NVRO earnings forecast.
How were Nevro's earnings last quarter?: Nevro Corp. (NYSE:NVRO) posted its earnings results on Sunday, November, 7th. The medical equipment provider reported ($0.86) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.87) by $0.01. The medical equipment provider had revenue of $93.21 million for the quarter, compared to analysts' expectations of $91.59 million. Nevro had a negative net margin of 35.96% and a negative trailing twelve-month return on equity of 43.73%. The company's quarterly revenue was down 14.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.29) EPS.
What guidance has Nevro issued on next quarter's earnings?: Nevro issued an update on its third quarter 2022 earnings guidance on Wednesday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $97.00 million-$101.00 million, compared to the consensus revenue estimate of $109.15 million.

What is D. Keith Grossman's approval rating as Nevro's CEO?: 9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees.
What other stocks do shareholders of Nevro own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).
What is Nevro's stock symbol?: Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."
Who are Nevro's major shareholders?: Nevro's stock is owned by many different institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (2.88%), Franklin Resources Inc. (2.76%), State Street Corp (2.29%), Principal Financial Group Inc. (1.86%), Brown Advisory Inc. (1.74%) and Credit Suisse AG (1.47%). Insiders that own company stock include Andrew H Galligan, D Keith Grossman, Doug Alleavitch, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends.
How do I buy shares of Nevro?: Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Nevro's stock price today?: One share of NVRO stock can currently be purchased for approximately $50.78.
How much money does Nevro make?: Nevro (NYSE:NVRO) has a market capitalization of $1.80 billion and generates $386.90 million in revenue each year. The medical equipment provider earns $-131,360,000.00 in net income (profit) each year or ($3.99) on an earnings per share basis.
How many employees does Nevro have?: The company employs 945 workers across the globe.
How can I contact Nevro?: Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The official website for the company is www.nevro.com. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at ir@nevro.com.

This page (NYSE:NVRO) was last updated on 8/19/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Nevro - NVRO Stock Forecast, Price & News

Nevro MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month